RE:RE:RE:RE:buck passedGreat opening , regarding learning from the past.
Onc is presently dealing with their Drug ( Pelareorep), as a co-therapy in multiple trials.
up until 3-4 years ago, majority of trials were single drug therapy.
with the addition of DNA analysis & many other genetic type of equipment & data, that did not exist even 5 yrs ago: they have advanced to studies.
How.
They formed the additional technical advisory panel. With global experts in oncology,
They have multiple co- therapy trials with Roche,Pfizer, BMS, Incyte & Merck.
These are all HUGE advantages to finding an opportunity & approval o& end use for Pela.
The above mentioned, minimal if not zero change to operating costs, Meaning best foot forward possible.
best example of that, most recent pancreatic cancer early results in trial alongside Roche.
if the additional patients show similar results ( due November of this year), Pelareorep alongside Roche becones a blockbuster drug.